Arformoterol tartrate in the treatment of COPD

Expert Review of Respiratory Medicine

Volumn 4, Issue 2, 2010, Pages 155-162

  Cazzola, Mario ^a,b   Hanania, Nicola A ^c   Matera, Maria G ^d  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Arformoterol; Clinical data; COPD; Enantiomers

Indexed keywords

ARFORMOTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; IPRATROPIUM BROMIDE; PLACEBO; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENANTIOMER; EVENING DOSAGE; FORCED EXPIRATORY VOLUME; HUMAN; LOW DRUG DOSE; MEDICAL NEBULIZER; MORNING DOSAGE; NERVOUSNESS; NONHUMAN; REVIEW; SIDE EFFECT; TREMOR;

EID: 77951439703     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.10.16     Document Type: Review

References (43)

1. Celli BR, MacNee W. ATS/ERS task force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 23, 932-946 (2004).
2. Rabe KF, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 176, 532-555 (2007).
3. National Asthma Education Prevention Program. Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma - summary report 2007. J. Allergy Clin. Immunol. 120(5 Suppl.), S94-S138 (2007).
4. Bateman ED, Hurd SS, Barnes PJ et al. Global strategy for asthma management and prevention: GINA executive summary. Eur. Respir. J. 31, 143-178 (2008).
5. Cazzola M, Matera MG, Ľtvall J. Ultra long-acting b2 agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs 14, 775-783 (2005).
6. Ameredes BT, Calhoun WJ. (R)-albuterol for asthma: pro. Am. J. Respir. Crit. Care Med. 174, 965-969 (2006).
7. Barnes PJ. Treatment with (R)-albuterol has no advantage over racemic albuterol. Am. J. Respir. Crit. Care Med. 174, 969-972 (2006).
8. Kelly HW. Levalbuterol for asthma: a better treatment? Curr. Allergy Asthma Rep. 7, 310-314 (2007).
9. Abbott MB, Levin RH, Miller JA. Point- counterpoint: a comparison of levalbuterol and racemic albuterol in the treatment of pediatric asthma. Pediatr. Rev. 25, 108-109 (2004).
10. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br. J. Pharmacol. 155, 291-299 (2008).
11. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur. Respir. J. 34, 757-769 (2009).
12. Handley DA, Senanayake CH, Dutczak W et al. Biological actions of formoterol isomers. Pulm. Pharmacol. Ther. 15, 135-145 (2002).
13. Mhanna MJ, Koester JF, Cohn RC. Effects of (R,R)- and (R,R/S,S)-formoterol on airway relaxation and contraction in an experimental rat model. Curr. Ther. Res. 68, 249-261 (2007).
14. Delmotte P, Sanderson MJ. Effects of formoterol on contraction and Ca2+ signaling of mouse airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 42(3), 373-381 (2009).
15. Ameredes BT, Calhoun WJ. Modulation of GM-CSF release by enantiomers of b-agonists in human airway smooth muscle. J. Allergy Clin. Immunol. 116, 65-72 (2005).
16. Steinke JW, Baramki D, Borish L. Opposing actions of (R,R)-isomers and (S,S)-isomers of formoterol on T-cell function. J. Allergy Clin. Immunol. 118, 963-965 (2006).
17. Abraha D, Cho SH, Agrawal DK, Park JM, Oh CK. (S,S)-formoterol increases the production of IL-4 in mast cells and the airways of a murine asthma model. Int. Arch. Allergy Immunol. 133, 380-388 (2004).
18. Cada DJ, Levien T, Baker DE. Arformoterol tartrate. Hosp. Pharm. 42, 447-454 (2007).
19. Brovana™, package insert. Sepracor Inc., MA, USA (2008).
20. Kharidia J, Fogarty CM, Laforce CF et al. A pharmacokinetic/ pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 21, 657-662 (2008).
21. Lötvall J, Palmqvist M, Ankerst J et al. The effect of formoterol over 24 h in patients with asthma: the role of enantiomers. Pulm. Pharmacol. Ther. 18, 109-113 (2005).
22. Baumgartner RA, Mazzetti A, Claus R, McVicar W, Hanrahan JP. Crossover dose-ranging study of arformoterol in patients with COPD (abstract). Proc. Am. Thorac. Soc. 3, A847 (2006).
23. Panettieri RA Jr, MacIntyre N, Sims M et al. Comparison of the efficacy and safety of arformoterol 15 -g twice daily and arformoterol 30-g once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study. Clin. Ther. 31, 1716-1723 (2009).
24. [No authors listed]. Arformoterol: (R,R)-eformoterol, (R,R)-formoterol, arformoterol tartrate, eformoterol-sepracor, formoterol-sepracor, R,R-eformoterol, R,R-formoterol. Drugs R D 5, 25-27 (2004).
25. Hanania NA, Donohue JF, Nelson H et al. The safety and efficacy of arformoterol and formoterol in COPD. J. COPD (2010) (In Press).
26. Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin. Ther. 29, 261-278 (2007).
27. Hanrahan JP, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Baumgartner RA. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD 5, 25-34 (2008).
28. Donohue JF, Hanania NA, Sciarappa KA et al. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance Ther. Adv. Respir. Dis. 2, 37-48 (2008).
29. Cazzola M, Tashkin DP. Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. J. COPD 6, 404-415 (2009).
30. Tashkin DP, Donohue JF, Mahler DA et al. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir. Med. 103, 516-524 (2009).
31. Hanrahan JP, Grogan D, Morganroth J, Cheng H, Baumgartner R. The effect of twice-daily nebulized arformoterol on QTC in subjects with COPD (abstract). Chest 132, 532-533 (2007).
32. Cazzola M, MacNee W, Martinez FJ et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 31, 416-469 (2008).
33. Hanrahan JP, Grogan DR, Baumgartner RA et al. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting b2-agonists arformoterol and salmeterol. Medicine (Baltimore) 87, 319-328 (2008).
34. Bauer A, McGlynn P, Bovet LL, et al. Output and aerosol properties of 5 nebulizer/compressor systems with arformoterol inhalation solution. Respir. Care. 54, 1342-1347 (2009).
35. Dolovich MB, Ahrens RC, Hess DR et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/ American College of Asthma, Allergy, and Immunology. Chest 127, 335-371 (2005).
36. Thorsson L, Geller D. Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: focus on budesonide. Respir. Med. 99, 836-849 (2005).
37. Zarowitz BJ. Nebulized respiratory medications: friend or foe? Geriatr. Nurs. 30, 45-49 (2009).
38. Brophy C, Kastelik JA, Gardiner E, Greenstone MA. Quality of life measurements and bronchodilator responsiveness in prescribing nebulizer therapy in COPD. Chron. Respir. Dis. 5, 13-18 (2008).
39. Tashkin DP, Klein GL, Colman SS, Zayed H, Schonfeld WH. Comparing COPD treatment: nebulizer, metered dose inhaler, and concomitant therapy. Am. J. Med. 120, 435-441 (2007).
40. Anonymous. Arformoterol (Brovana) for COPD. Med. Lett. 49, 53-54 (2007).
41. Matera MG, Cazzola M. Ultra-long-acting b2-adrenoceptor agonists. An emerging therapeutic option for asthma and COPD? Drugs 67, 503-515 (2007).
42. Molfino NA. Drugs in clinical development for chronic obstructive pulmonary disease. Respiration 72, 105-112 (2005).
43. Tashkin DP, Littner M, Andrews CP, Tomlinson L, Rinehart M, Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir. Med. 102, 479-487 (2008).